华蟾素注射液联合化疗药物治疗中晚期非小细胞肺癌的Meta 分析

目的根据现有临床资料系统评价华蟾素注射液联合化疗作为中晚期非小细胞肺癌(NSCLC)治疗方案的疗效及安全性。方法电子检索Medline(1966～2011)、Cochrane Library(2011年第11期)、CNKI(1978～2011)、维普(1989～2011)、万方(1988～2011)、CBMdisc(1978～2011)等数据库,对符合纳入标准的随机对照试验(RCT),采用RevMan5.0.2软件进行Meta分析。结果通过阅读文题、摘要及全文后,最终共纳入7个RCT,共498例患者。Meta分析结果显示:试验组和对照组在近期(6个月)疗效RR=1.29,95%CI(1.07,1.56)]、治疗前后卡氏评分RR=1.86,95%CI(1.14,3.05)]、体重增加RR=1.56,95%CI(1.20,2.03)]、胃肠道反应RR=0.72,95%CI(0.53,0.99)]、白细胞减少RR=0.70,95%CI(0.54,0.91)]、血小板减少RR=0.53,95%CI(0.38,0.75)]、肾功能异常RR=0.37,95%CI(0.17,0.79)]等反面差异具有统计学意义,在肝功能异常RR=0.59,95%CI(0.26,1.34)]、神经毒性RR=0.74,95%CI(0.32,1.75)]等方面差异无统计学意义。结论华蟾素注射液联合化疗适于晚期NSCLC的治疗,能提高近期疗效,提高卡氏评分,增加体重,并且减少胃肠道反应、白细胞减少、血小板减少等毒副作用。

Meta-Analysis of Cinobufacini Injection plus Chemotherapy in the Treatment of Non-small-cell Lung Cancer

Objective To evaluate the efficacy and safety of cinobufacini injection combined with chemotherapy as the treatment for advanced non-small-cell lung cancer(NSCLC) based on existing clinical information.Method Electronically searches databases,such as Medline(1966~2011),Cochrane Library(2011,Issue 11),CNKI(1978~2011),VIP(1989~2011),Wanfang Data(1988~2011),CBMdisc(1978~2011),and uses RevMan 5.0.2 software to undertake meta-analysis with included randomized controlled trials(RCT).Results Totally seven RCT of 498 patients were included finally after reading the title,abstract and full text.Meta-analysis results show that the experimental group and control group have significant differences in the response rateRR=1.29,95%CI(1.07,1.56)],Karnofsky scoreRR=1.86,95%CI(1.14,3.05)],weight changeRR=1.56,95%CI(1.20,2.03)],gastrointestinal side effectsRR=0.72,95%CI(0.53,0.99)],neutropeniaRR=0.70,95%CI(0.54,0.91)],thrombocytopeniaRR=0.53,95%CI(0.38,0.75)],abnormal renal functionRR=0.37,95%CI(0.17,0.79)],and have no significant differences in abnormal liver functionRR=0.59,95%CI(0.26,1.34)] and neurotoxicityRR=0.74,95%CI(0.32,1.75)].Conclusion Cinobufacini combined with chemotherapy is suitable for advanced NSCLC by improving the response rate,increasing Karnofsky score,gaining weight and reducing major side effects.